Adimmune Corporation 2025 Q4 Financial Report
Key facts
- Adimmune Corporation 2025 Q4 Financial Report
- Adimmune Corporation reported a basic EPS of -0.57 NTD and a net loss of 330 million NTD for Q4 2025, despite achieving operating revenue of 1.402 billion NTD.
- Source: PR Times
- Date: December 1, 2025
Direct answer
Adimmune Corporation reported a basic EPS of -0.57 NTD and a net loss of 330 million NTD for Q4 2025, despite achieving operating revenue of 1.402 billion NTD.
- Citation
- Adimmune Corporation 2025 Q4 Financial Report (December 1, 2025), PR Times
- Source
- PR Times
- Date
- December 1, 2025
Adimmune Corporation reported a basic EPS of -0.57 NTD and a net loss of 330 million NTD for Q4 2025, despite achieving operating revenue of 1.402 billion NTD.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Company Code: 4142. Company Name: Adimmune Corporation. Industry: Biotechnology and Medical Care Industry. Year/Quarter: 2025 Q4. Basic Earnings Per Share: -0.57 NTD. Operating Revenue: 1.402 billion NTD. Net Profit After Tax: -0.330 billion NTD.
FAQ
What are the key facts in this article?
Adimmune Corporation reported a basic EPS of -0.57 NTD and a net loss of 330 million NTD for Q4 2025, despite achieving operating revenue of 1.402 billion NTD.
What is the direct answer?
Adimmune Corporation reported a basic EPS of -0.57 NTD and a net loss of 330 million NTD for Q4 2025, despite achieving operating revenue of 1.402 billion NTD.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-4142-2025Q4 | December 1, 2025